Cybin Inc. (NASDAQ:HELP) Given Consensus Rating of “Buy” by Brokerages

Cybin Inc. (NASDAQ:HELP) has been given a consensus rating of “Buy” by the six research firms that are currently covering the company, Marketbeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have covered the stock in the last year is $46.3333.

Several equities research analysts have recently weighed in on HELP shares. Wells Fargo & Company assumed coverage on Cybin in a report on Monday, July 27th. They issued an “overweight” rating and a $16.00 target price for the company. Wall Street Zen raised Cybin from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 29th. TD Cowen lifted their price objective on Cybin from $8.00 to $62.00 and gave the company a “buy” rating in a report on Thursday, August 20th. Finally, Barclays assumed coverage on shares of Cybin in a research note on Friday. They issued an “overweight” rating and a $35.00 target price on the stock.

More Cybin News

Here are the key news stories impacting Cybin this week:

• Positive Sentiment: CEO Michael Halstead purchased 100,000 shares at an average price of $13.47, investing approximately $1.35 million and increasing his direct holdings by about 146%. The sizable open-market purchase may be viewed as a signal of management confidence in Cybin’s outlook. SEC Form 4 filing
• Positive Sentiment: Helus Pharma presented four analyses of HLP003, an investigational oral deuterated psilocin analog, at Psych Congress 2026. The presentations further characterize HLP003 and the Phase 3 PARADIGM program, which is evaluating the treatment as an adjunctive therapy for major depressive disorder. Additional clinical data may support the company’s development strategy, although HLP003 remains investigational and faces clinical and regulatory risks. HLP003 Psych Congress presentation
• Positive Sentiment: Cybin is scheduled to participate in the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, where Halstead will join a fireside chat. The event provides an opportunity to discuss the company’s serotonergic pipeline with investors and analysts. TD Cowen summit announcement
• Neutral Sentiment: Brokerage coverage has expanded, with Barclays initiating coverage and brokerages assigning a reported average price target of $48.60. These targets can improve visibility, but they are estimates rather than guarantees of future performance. Barclays coverage initiation

Cybin Stock Up 10.4%

NASDAQ HELP opened at $13.66 on Tuesday. The stock has a market cap of $1.08 billion, a P/E ratio of -4.52 and a beta of 0.63. The company’s 50-day simple moving average is $10.81 and its 200 day simple moving average is $7.14. Cybin has a twelve month low of $3.76 and a twelve month high of $15.15.

Cybin (NASDAQ:HELP) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.91) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.11). Research analysts anticipate that Cybin will post -2.95 earnings per share for the current year.

Insider Activity at Cybin

In other news, CEO Michael Halstead purchased 100,000 shares of Cybin stock in a transaction on Monday, September 21st. The shares were purchased at an average cost of $13.47 per share, for a total transaction of $1,347,000.00. Following the completion of the transaction, the chief executive officer directly owned 168,568 shares in the company, valued at approximately $2,270,610.96. This represents a 145.84% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Paul Glavine purchased 100,000 shares of Cybin stock in a transaction on Tuesday, September 8th. The stock was purchased at an average price of $12.47 per share, for a total transaction of $1,247,000.00. Following the completion of the transaction, the insider owned 4,271,252 shares of the company’s stock, valued at approximately $53,262,512.44. This represents a 2.40% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought 685,000 shares of company stock valued at $8,384,100 in the last ninety days. Insiders own 15.00% of the company’s stock.

Institutional Investors Weigh In On Cybin

A hedge fund recently bought a new position in Cybin stock. Pale Fire Capital SE acquired a new position in Cybin Inc. (NASDAQ:HELP) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 153,505 shares of the company’s stock, valued at approximately $1,015,000. Pale Fire Capital SE owned approximately 0.21% of Cybin as of its most recent filing with the Securities and Exchange Commission (SEC). 17.94% of the stock is owned by hedge funds and other institutional investors.

About Cybin

Cybin Inc is a clinical-stage biopharmaceutical company focused on developing psychedelic-based therapeutics for the treatment of mental health conditions. The company combines drug discovery, clinical development and proprietary formulation technologies to design potentially more efficient and scalable psychedelic treatments.

Cybin’s development programs have included CYB003, an investigational deuterated psilocybin analog being studied for major depressive disorder, and CYB004, an investigational deuterated DMT molecule being evaluated for generalized anxiety disorder and other mental health indications.